A 2022 sub-analysis from the CLUSTER-HF study analyzed NT-proBNP levels at discharge in a subgroup of 94 patients, finding that a smaller absolute decrease in NT-proBNP (less than 3350 pg/mL) at discharge from hospitalization for heart failure was associated with fewer clinical events at 180 days (emergency visits, rehospitalization for heart failure, and death from any cause); however, this sub-analysis did not examine the relationship between NT-proBNP at discharge and ventricular function at follow-up [27]. The gene discussed is NPPB; the disease is hydrops fetalis.